CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

GSK ends brain drug alliance with Alector

PartnershipnegativeNegative
AI Analysis

Summary

GSK has ended its brain drug alliance with Alector due to clinical setbacks, terminating a partnership that was valued at up to $2.2 billion and represented GSK's return to neuroscience.

Outcome Details

Clinical setbacks derailed alliance; GSK ends brain drug partnership with Alector

Importance:7/10
Sentiment:
-0.85
partnership terminationclinical setbackneuroscienceGSKAlector
Related Companies

Read the original article

Published by BioPharma Dive on July 9, 2026 3:45 PM

Read Original